Note
In vitro activity of juglone (5-hydroxy-1,4-naphthoquinone) against both fluconazole-resistant and susceptible Candida isolates
Actividad in vitro de juglona (5-hidroxi-1,4-naftoquinona) contra aislamientos de Candida resistentes y sensibles a fluconazol
Afsane Vaezia, Masoud Moghadaszadehb, Elahe Nasric, Shima Gharibid, Kambiz Dibae, Adam Matkowskif, Hamed Fakhime,g,
Corresponding author
a Department of Medical Laboratory Science, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
b Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
c Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
d Core Research Facilities, Isfahan University of Medical Sciences, Isfahan, Iran
e Department of Medical Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
f Department of Pharmaceutical Biology and Botanical Garden of Medicinal Plants, Wroclaw Medical University, Wrocław, Poland
g Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Read
727
Timeswas read the article
144
Total PDF
583
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 December | 19 | 20 | 39 |
| 2024 November | 29 | 2 | 31 |
| 2024 October | 24 | 12 | 36 |
| 2024 September | 37 | 11 | 48 |
| 2024 August | 32 | 5 | 37 |
| 2024 July | 22 | 6 | 28 |
| 2024 June | 32 | 6 | 38 |
| 2024 May | 24 | 11 | 35 |
| 2024 April | 23 | 3 | 26 |
| 2024 March | 22 | 5 | 27 |
| 2024 February | 22 | 3 | 25 |
| 2024 January | 19 | 1 | 20 |
| 2023 December | 18 | 9 | 27 |
| 2023 November | 36 | 5 | 41 |
| 2023 October | 47 | 4 | 51 |
| 2023 September | 23 | 3 | 26 |
| 2023 August | 14 | 2 | 16 |
| 2023 July | 26 | 5 | 31 |
| 2023 June | 17 | 8 | 25 |
| 2023 May | 51 | 8 | 59 |
| 2023 April | 42 | 3 | 45 |
| 2023 March | 1 | 4 | 5 |
| 2023 February | 0 | 2 | 2 |
| 2022 December | 1 | 0 | 1 |
| 2022 September | 0 | 2 | 2 |
| 2022 August | 2 | 4 | 6 |
Show all
